Biogen Inc (BIIB)

250.04
0.05 0.02
NASDAQ : Health Care
Prev Close 250.09
Open 250.69
Day Low/High 249.00 / 251.00
52 Wk Low/High 223.02 / 338.51
Volume 1.33M
Avg Volume 1.55M
Exchange NASDAQ
Shares Outstanding 212.12M
Market Cap 53.62B
EPS 17.00
P/E Ratio 15.84
Div & Yield N.A. (N.A)

Latest News

Biogen To Present At The Bernstein 33rd Annual Strategic Decisions Conference

Biogen To Present At The Bernstein 33rd Annual Strategic Decisions Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Bernstein 33 rd Annual Strategic Decisions Conference.

Biogen Acquires Remedy Pharmaceuticals' CIRARA™ For Large Hemispheric Stroke

Biogen Acquires Remedy Pharmaceuticals' CIRARA™ For Large Hemispheric Stroke

Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, CIRARA™ (intravenous glyburide).

Insiders Are Loading Up on Twitter, Biogen & More

Insiders Are Loading Up on Twitter, Biogen & More

Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Biogen's new spine disease drug outperformed expectations during its commercial debut.

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.

Stock Futures See More Gains on a Stream of Positive Earnings

Stock Futures See More Gains on a Stream of Positive Earnings

Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.

Biogen Reports First Quarter 2017 Revenues Of $2.8 Billion

Biogen Reports First Quarter 2017 Revenues Of $2.8 Billion

Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2017 financial results, including: Total revenues of $2.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures rise and European shares are mostly higher as global markets rally in the wake of Emmanuel Macron's victory in the first round of France's presidential elections.

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.

Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function In Children With Later-Onset Spinal Muscular Atrophy

Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function In Children With Later-Onset Spinal Muscular Atrophy

Biogen (NASDAQ:BIIB) will present Phase 3 end of study SPINRAZA ® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in...

TECFIDERA® And TYSABRI® Data Demonstrate Improved Outcomes With Early MS Treatment

TECFIDERA® And TYSABRI® Data Demonstrate Improved Outcomes With Early MS Treatment

Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA ® (dimethyl fumarate) and TYSABRI ® (natalizumab), early in the course...

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Biogen's SPINRAZA® (nusinersen) Receives Positive CHMP Opinion For The Treatment Of Spinal Muscular Atrophy

Biogen's SPINRAZA® (nusinersen) Receives Positive CHMP Opinion For The Treatment Of Spinal Muscular Atrophy

Biogen (NASDAQ: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorization...

Biogen Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress

Biogen Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress

Biogen (NASDAQ: BIIB) will present data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the 69th annual meeting of the American...

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Why Biotech Investors Should Worry When Their Stocks Turn Boring

Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Biogen To Present Data At The 13th International Conference On Alzheimer's And Parkinson's Diseases

Biogen To Present Data At The 13th International Conference On Alzheimer's And Parkinson's Diseases

Biogen (NASDAQ: BIIB) will present data from its Alzheimer's and Parkinson's disease programs at the 13 th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria March 29 -...

Biogen To Report First Quarter 2017 Financial Results On April 25, 2017

Biogen To Report First Quarter 2017 Financial Results On April 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open.